ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.

LIPO Lipella Pharmaceuticals Inc

0.75
0.00 (0.00%)
Pre Mercado
Última actualización: 03:00:00
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Lipella Pharmaceuticals Inc LIPO NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
0.00 0.00% 0.75 03:00:00
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
0.75
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
17/4/202407:00GLOBELipella Pharmaceuticals Expands its Advisory Board to..
05/4/202407:00GLOBELipella Pharmaceuticals to Publish Abstract Detailing..
03/4/202407:00GLOBELipella Pharmaceuticals Announces FDA Type C Meeting for..
07/3/202414:23GLOBEPRISM MarketView Spotlights Lipella Pharmaceuticals as it..
06/3/202416:05EDGAR2Form SC 13D/A - General statement of acquisition of..
06/3/202416:03EDGAR2Form SC 13D/A - General statement of acquisition of..
05/3/202407:00GLOBELipella Pharmaceuticals Announces FDA Clearance of IND for..
27/2/202416:04EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
27/2/202415:51EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
20/2/202407:00GLOBELipella Pharmaceuticals to Present at PropThink Digital..
08/2/202423:15EDGAR2Form EFFECT - Notice of Effectiveness
07/2/202416:29EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
01/2/202415:09EDGAR2Form S-3 - Registration statement under Securities Act of..
25/1/202415:06EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
03/1/202415:59EDGAR2Form SC 13G - Statement of acquisition of beneficial..
20/12/202307:00GLOBELipella Pharmaceuticals Marks Successful First Year with..
28/11/202316:28EDGAR2Form 8-K - Current report
22/11/202315:05EDGAR2Form 8-K - Current report
14/11/202305:22EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
14/11/202305:14EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
10/11/202307:00PRNUSFDA Grants Orphan Designation for Lipella's LP-310 Drug..
09/11/202315:07EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
01/11/202315:06EDGAR2Form S-1 - General form for registration of securities under..
25/10/202315:05PRNUSLipella Pharmaceuticals Announces Closing of $2 Million..
24/10/202307:00PRNUSLipella Pharmaceuticals Announces $2 Million Private..
20/10/202307:00PRNUSLipella Pharmaceuticals Announces FDA Clearance of IND for..
10/10/202315:05EDGAR2Form DEF 14A - Other definitive proxy statements
21/9/202307:30PRNUSLipella Pharmaceuticals' Phase 2a Clinical Study Results..
11/9/202306:38EDGAR2Form 8-K - Current report
14/8/202315:16EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
14/8/202315:04EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/8/202315:30EDGAR2Form 8-K - Current report
02/8/202315:05EDGAR2Form 8-K - Current report
15/5/202308:17PRNUSLipella Pharmaceuticals Reports First Quarter 2023 Financial..

Su Consulta Reciente

Delayed Upgrade Clock